FRAGILE X SYNDROME NEWSLETTER | FXS Newsletter


FRAGILE X SYNDROME NEWSLETTER

Fragile X Syndrome, a syndrome, which results in intellectual disabilities as well as affects the physical characteristics of the people suffering from it, is a result of mutation associated with the gene known as FMR1.


As per DelveInsight assessments, the market size of Fragile X Syndrome (FXS) in the 7MM was found to be USD 33.51 Million in 2017, for the study period, 2017–2028.

Top companies involved fuelling the FXS Market are:

Tetra Therapeutics, Zynerba Pharmaceuticals, Ovid Therapeutics, Confluence Pharmaceuticals, Neuren Pharmaceuticals, and others.

Through its Newsletter series, DelveInsight aims to brings to light an overview of Fragile X syndrome, along with its epidemiological scenario, treatment landscape and upcoming therapies in the pipeline that shall drive the market forward.

Visit to gain access to our Newsletter: https://www.delveinsight.com/whitepaper-newsletter/fragile-x-syndrome

Fragile X Syndrome Newsletter



Comments

Popular posts from this blog

How Competitive intelligence is transforming the scenario for Biotech firms?

Hypothalamic Obesity Market by DelveInsight

Test